Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update.
BioArctic AB reported significant financial growth in Q1 2025, driven by the approval and commercial success of its Alzheimer’s treatment, Leqembi, in the EU and other markets. The company also benefited from a lucrative license agreement with Bristol Myers Squibb, contributing to a substantial increase in net revenues and operating profit, positioning BioArctic as a key player in the neurodegenerative disease treatment market.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer’s disease. The company collaborates with partners like Eisai and Bristol Myers Squibb to advance its portfolio of innovative therapies, such as Leqembi and exidavnemab, with a strong emphasis on research and development.
Average Trading Volume: 277,381
Current Market Cap: SEK16.29B
Learn more about BIOA.B stock on TipRanks’ Stock Analysis page.